Shots:

• Wuxi Vaccines to establish new manufacturing facility which includes drug substance manufacturing (DS)- drug product manufacturing (DP)- manufacture science and technology labs (MS&T) as well as quality control labs (QC)
• The facility will develop and manufacture partner’s vaccine therapy for the global market. The new facility is expected to be operational in 2022
• Additionally- in Nov’2019- Wuxi invests $240M to establish a new vaccine manufacturing facility in Ireland. Wuxi biologics will provide its global partners with a robust and premier-quality supply chain network to develop high-quality vaccines protecting humans globally

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Bio Spectrum Asia